Evogene Reports Second Quarter 2025 Financial Results
1. Evogene announced 2025 financial results indicating revenue growth. 2. Cost reduction initiatives led to decreased operational expenses. 3. Strategic focus is on ChemPass AI for pharmaceuticals and agriculture. 4. Sale of Lavie Bio enhanced cash reserves significantly. 5. Long-term growth is anticipated from academic and industry collaborations.